Seres Therapeutics, Inc. (MCRB): Total Assets
$138.19M
As of 2025-12-31
$101.59M
As of 2026-06-30
-26.6%
3-year compound annual growth
-16.6%
5-year compound annual growth
-4.4%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $138.19M | -1.2% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $139.81M | -61.0% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $358.60M | +2.8% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $348.78M | -1.7% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $354.86M | +3.5% | 2023-03-07, Balance as of period end |
| 2020-12-31 | $342.94M | +158.9% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $132.44M | +9.9% | 2021-03-02, Balance as of period end |
| 2018-12-31 | $120.47M | -36.4% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $189.52M | -30.5% | 2019-03-06, Balance as of period end |
| 2016-12-31 | $272.65M | +25.7% | 2018-03-08, Balance as of period end |
| 2015-12-31 | $216.90M | +84.8% | 2017-03-16, Balance as of period end |
| 2014-12-31 | $117.34M | n/a | 2016-03-14, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | 2025-12-31 | $138.19M | -1.2% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $138.29M | +43.5% |
| Monopar Therapeutics (MNPR) | 2025-12-31 | $140.72M | +133.4% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $141.31M | -19.5% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $131.44M | -35.1% |
| Larimar Therapeutics, Inc. (LRMR) | 2025-12-31 | $145.84M | -27.2% |
| Citius Pharmaceuticals, Inc. (CTXR) | 2025-09-30 | $130.94M | +12.2% |
| Acrivon Therapeutics, Inc. (ACRV) | 2025-12-31 | $129.72M | -34.0% |
| XBiotech Inc. (XBIT) | 2025-12-31 | $150.08M | -24.6% |
Compare MCRB, ELTP, MNPR, PRLD side by side · Screen every company in Pharmaceutical Preparations ↗